Jacqueline Fu

Represented Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, in connection with a privatization project of US$300 million value conducted through share swap transactions with Woods Investment, with sources of funds from its major shareholders and PAG, a global alternative investment firm. It successfully delisted from both Taipei Exchange and Nasdaq and the privatization project was completed on October 8, 2021.

Acted as Taiwan counsel to Taiwan Liposome Company Ltd in its ADSs listing on the Nasdaq Stock Market.

Represent Mirae Asset's sale of its Taiwan subsidiary to Amundi Asset.

Represented Handa Pharmaceuticals in PHARMIRA LABORATORIES, INC’s acquisition of Handa and subsequent equity financing.

Represented GE Aircraft Engine in its joint venture with Evergreen International Corporation, a subsidiary of EVA Airways.

Represented ACT Genomics in its corporate restructuring and equity financing.

Represented Taiwan listed company in bidding on acquisition of McDonalds restaurants in Taiwan.

Represented a discovery-based and market-focused pharmaceutical company in its Series A, B, and C preferred stock equity financings totaling US$120 million.

Represented Sequoia Capital in its investments in Appier and Pinko.

Represented Intel Capital in Taiwan in relation to Asia Pacific venture capital transactions.

Represented CERATIZIT in its acquisition of a 50% stake in carbide manufacturer CB Carbide, including eight factories and a dozen sales offices.

Represent Sartorius in acquisition of its Taiwan distributor.

Represented the bidder company on the acquisitions of AIG Insurance and Metlife Inc.

Represented Taiwan listed company in its acquisition of MassMutual Mercuries Life Insurance.

Represented General Motors in its acquisition of the dealer distribution network of China Automobile Co., Ltd. throughout Taiwan.

Represented a global leader in engineered materials and optoelectronic components in its acquisition of a global leader in wavelength selective switches for US$85 million.

Acted as Issuer Counsel to Aslan Pharmaceuticals in its listing on the Taipei Exchange.

Acted as Taiwan counsel to a clinical-stage immunology-focused biopharmaceutical company in its ADS initial offering of US$42 million on the Nasdaq Stock Market.